Ischemia Reversal Program (IRP) in patients suffering from Ischemic Heart Disease (IHD) with known history of Hypertension: A Retrospective Study

Abstract

Introduction: Cardiovascular mortality has risen in the last few years and Ischemic Heart Disease (IHD) is one of the most common causes. Ischemia Reversal Program (IRP) kit uses a combination of Snehana (Centripetal oleation), Swedana (Thermal vasodilation) and Basti (Per rectal drug administration) for providing relief to IHD patients. This study was conducted to evaluate the efficacy of IRP in IHD patients. Methods: This retrospective study included data of patients having positive inducible ischemia by stress test with known history of hypertension (HTN) and had visited the Madhavbaug clinics. A minimum of 7 IRP sittings were needed for inclusion. Duke Treadmill score, VO2 max, systolic plus diastolic blood pressure (SBP, DBP) and details of conventional medications were noted on day 1 and on day 90 followed by comparison between these values. Results: 19 patients having mean age 59.26 ± 8.03 years were enrolled, with 78.9% being males. On day 90, none of the patients were at high risk by Duke Treadmill Score, compared to 47.4% being at high risk on day 1 (p<0.01). Mean VO2 max significantly increased on day 90 of IRP therapy (p<0.01) while mean SBP and DBP decreased, though not significantly (p>0.05). The number of subjects on allopathic medicines decreased after 90^th day, as compared to day 1. Conclusion: IRP treatment is associated with significant improvement in the Duke Treadmill score and VO₂ max, thereby leading to betterment of prognosis in IHD patients. The dependency on conventional medicines was also decreased by IRP.